Inhaled PGE<inf>1</inf> in neonates with hypoxemic respiratory failure

Two pilot feasibility randomized clinical trials

Beena G. Sood, Martin Keszler, Meena Garg, Jonathan M. Klein, Robin Ohls, Namasivayam Ambalavanan, C. Michael Cotten, Monica Malian, Pablo J. Sanchez, Satyan Lakshminrusimha, Leif D. Nelin, Krisa P. Van Meurs, Rebecca Bara, Shampa Saha, Abhik Das, Dennis Wallace, Rosemary D. Higgins, Seetha Shankaran

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants. Aerosolized prostaglandins I<inf>2</inf> (PGI<inf>2</inf>) and E<inf>1</inf> (PGE<inf>1</inf>) have been reported to be effective selective pulmonary vasodilators. The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE<inf>1</inf> (IPGE<inf>1</inf>) in NHRF. Methods: Two pilot multicenter phase II RCTs are included in this report. In the first pilot, late preterm and term neonates with NHRF, who had an oxygenation index (OI) of ≥15 and <25 on two arterial blood gases and had not previously received INO, were randomly assigned to receive two doses of IPGE<inf>1</inf> (300 and 150 ng/kg/min) or placebo. The primary outcome was the enrollment of 50 infants in six to nine months at 10 sites. The first pilot was halted after four months for failure to enroll a single infant. The most common cause for non-enrollment was prior initiation of INO. In a re-designed second pilot, co-administration of IPGE<inf>1</inf> and INO was permitted. Infants with suboptimal response to INO received either aerosolized saline or IPGE<inf>1</inf> at a low (150 ng/kg/min) or high dose (300 ng/kg/min) for a maximum duration of 72 hours. The primary outcome was the recruitment of an adequate number of patients (n = 50) in a nine-month-period, with fewer than 20% protocol violations. Results: No infants were enrolled in the first pilot. Seven patients were enrolled in the second pilot; three in the control, two in the low-dose IPGE<inf>1</inf>, and two in the high-dose IPGE<inf>1</inf> groups. The study was halted for recruitment futility after approximately six months as enrollment targets were not met. No serious adverse events, one minor protocol deviation and one pharmacy protocol violation were reported. Conclusions: These two pilot RCTs failed to recruit adequate eligible newborns with NHRF. Complex management RCTs of novel therapies for persistent pulmonary hypertension of the newborn (PPHN) may require novel study designs and a longer period of time from study approval to commencement of enrollment. Trial registration: ClinicalTrials.gov: Pilot one: NCT number: 00598429. registered on 10 January 2008. Last updated: 3 February 2011.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalTrials
DOIs
StateAccepted/In press - Dec 12 2014

Fingerprint

Alprostadil
Epoprostenol
Respiratory Insufficiency
Randomized Controlled Trials
Newborn Infant
Nitric Oxide
Vasodilator Agents
Persistent Fetal Circulation Syndrome
Medical Futility
Lung
Time and Motion Studies
Placebos
Therapeutics

Keywords

  • Aerosols
  • Clinical trial
  • Hypoxemic respiratory failure
  • Nebulizers
  • Neonatal
  • Prostaglandins
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Cite this

Inhaled PGE<inf>1</inf> in neonates with hypoxemic respiratory failure : Two pilot feasibility randomized clinical trials. / Sood, Beena G.; Keszler, Martin; Garg, Meena; Klein, Jonathan M.; Ohls, Robin; Ambalavanan, Namasivayam; Cotten, C. Michael; Malian, Monica; Sanchez, Pablo J.; Lakshminrusimha, Satyan; Nelin, Leif D.; Van Meurs, Krisa P.; Bara, Rebecca; Saha, Shampa; Das, Abhik; Wallace, Dennis; Higgins, Rosemary D.; Shankaran, Seetha.

In: Trials, 12.12.2014, p. 1-14.

Research output: Contribution to journalArticle

Sood, BG, Keszler, M, Garg, M, Klein, JM, Ohls, R, Ambalavanan, N, Cotten, CM, Malian, M, Sanchez, PJ, Lakshminrusimha, S, Nelin, LD, Van Meurs, KP, Bara, R, Saha, S, Das, A, Wallace, D, Higgins, RD & Shankaran, S 2014, 'Inhaled PGE<inf>1</inf> in neonates with hypoxemic respiratory failure: Two pilot feasibility randomized clinical trials', Trials, pp. 1-14. https://doi.org/10.1186/1745-6215-15-486
Sood, Beena G. ; Keszler, Martin ; Garg, Meena ; Klein, Jonathan M. ; Ohls, Robin ; Ambalavanan, Namasivayam ; Cotten, C. Michael ; Malian, Monica ; Sanchez, Pablo J. ; Lakshminrusimha, Satyan ; Nelin, Leif D. ; Van Meurs, Krisa P. ; Bara, Rebecca ; Saha, Shampa ; Das, Abhik ; Wallace, Dennis ; Higgins, Rosemary D. ; Shankaran, Seetha. / Inhaled PGE<inf>1</inf> in neonates with hypoxemic respiratory failure : Two pilot feasibility randomized clinical trials. In: Trials. 2014 ; pp. 1-14.
@article{180f4011b2094ba7ae0967d0b89b1454,
title = "Inhaled PGE1 in neonates with hypoxemic respiratory failure: Two pilot feasibility randomized clinical trials",
abstract = "Background: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46{\%} of infants. Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1) have been reported to be effective selective pulmonary vasodilators. The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE1 (IPGE1) in NHRF. Methods: Two pilot multicenter phase II RCTs are included in this report. In the first pilot, late preterm and term neonates with NHRF, who had an oxygenation index (OI) of ≥15 and <25 on two arterial blood gases and had not previously received INO, were randomly assigned to receive two doses of IPGE1 (300 and 150 ng/kg/min) or placebo. The primary outcome was the enrollment of 50 infants in six to nine months at 10 sites. The first pilot was halted after four months for failure to enroll a single infant. The most common cause for non-enrollment was prior initiation of INO. In a re-designed second pilot, co-administration of IPGE1 and INO was permitted. Infants with suboptimal response to INO received either aerosolized saline or IPGE1 at a low (150 ng/kg/min) or high dose (300 ng/kg/min) for a maximum duration of 72 hours. The primary outcome was the recruitment of an adequate number of patients (n = 50) in a nine-month-period, with fewer than 20{\%} protocol violations. Results: No infants were enrolled in the first pilot. Seven patients were enrolled in the second pilot; three in the control, two in the low-dose IPGE1, and two in the high-dose IPGE1 groups. The study was halted for recruitment futility after approximately six months as enrollment targets were not met. No serious adverse events, one minor protocol deviation and one pharmacy protocol violation were reported. Conclusions: These two pilot RCTs failed to recruit adequate eligible newborns with NHRF. Complex management RCTs of novel therapies for persistent pulmonary hypertension of the newborn (PPHN) may require novel study designs and a longer period of time from study approval to commencement of enrollment. Trial registration: ClinicalTrials.gov: Pilot one: NCT number: 00598429. registered on 10 January 2008. Last updated: 3 February 2011.",
keywords = "Aerosols, Clinical trial, Hypoxemic respiratory failure, Nebulizers, Neonatal, Prostaglandins, Pulmonary hypertension",
author = "Sood, {Beena G.} and Martin Keszler and Meena Garg and Klein, {Jonathan M.} and Robin Ohls and Namasivayam Ambalavanan and Cotten, {C. Michael} and Monica Malian and Sanchez, {Pablo J.} and Satyan Lakshminrusimha and Nelin, {Leif D.} and {Van Meurs}, {Krisa P.} and Rebecca Bara and Shampa Saha and Abhik Das and Dennis Wallace and Higgins, {Rosemary D.} and Seetha Shankaran",
year = "2014",
month = "12",
day = "12",
doi = "10.1186/1745-6215-15-486",
language = "English (US)",
pages = "1--14",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Inhaled PGE1 in neonates with hypoxemic respiratory failure

T2 - Two pilot feasibility randomized clinical trials

AU - Sood, Beena G.

AU - Keszler, Martin

AU - Garg, Meena

AU - Klein, Jonathan M.

AU - Ohls, Robin

AU - Ambalavanan, Namasivayam

AU - Cotten, C. Michael

AU - Malian, Monica

AU - Sanchez, Pablo J.

AU - Lakshminrusimha, Satyan

AU - Nelin, Leif D.

AU - Van Meurs, Krisa P.

AU - Bara, Rebecca

AU - Saha, Shampa

AU - Das, Abhik

AU - Wallace, Dennis

AU - Higgins, Rosemary D.

AU - Shankaran, Seetha

PY - 2014/12/12

Y1 - 2014/12/12

N2 - Background: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants. Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1) have been reported to be effective selective pulmonary vasodilators. The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE1 (IPGE1) in NHRF. Methods: Two pilot multicenter phase II RCTs are included in this report. In the first pilot, late preterm and term neonates with NHRF, who had an oxygenation index (OI) of ≥15 and <25 on two arterial blood gases and had not previously received INO, were randomly assigned to receive two doses of IPGE1 (300 and 150 ng/kg/min) or placebo. The primary outcome was the enrollment of 50 infants in six to nine months at 10 sites. The first pilot was halted after four months for failure to enroll a single infant. The most common cause for non-enrollment was prior initiation of INO. In a re-designed second pilot, co-administration of IPGE1 and INO was permitted. Infants with suboptimal response to INO received either aerosolized saline or IPGE1 at a low (150 ng/kg/min) or high dose (300 ng/kg/min) for a maximum duration of 72 hours. The primary outcome was the recruitment of an adequate number of patients (n = 50) in a nine-month-period, with fewer than 20% protocol violations. Results: No infants were enrolled in the first pilot. Seven patients were enrolled in the second pilot; three in the control, two in the low-dose IPGE1, and two in the high-dose IPGE1 groups. The study was halted for recruitment futility after approximately six months as enrollment targets were not met. No serious adverse events, one minor protocol deviation and one pharmacy protocol violation were reported. Conclusions: These two pilot RCTs failed to recruit adequate eligible newborns with NHRF. Complex management RCTs of novel therapies for persistent pulmonary hypertension of the newborn (PPHN) may require novel study designs and a longer period of time from study approval to commencement of enrollment. Trial registration: ClinicalTrials.gov: Pilot one: NCT number: 00598429. registered on 10 January 2008. Last updated: 3 February 2011.

AB - Background: Inhaled nitric oxide (INO), a selective pulmonary vasodilator, has revolutionized the treatment of neonatal hypoxemic respiratory failure (NHRF). However, there is lack of sustained improvement in 30 to 46% of infants. Aerosolized prostaglandins I2 (PGI2) and E1 (PGE1) have been reported to be effective selective pulmonary vasodilators. The objective of this study was to evaluate the feasibility of a randomized controlled trial (RCT) of inhaled PGE1 (IPGE1) in NHRF. Methods: Two pilot multicenter phase II RCTs are included in this report. In the first pilot, late preterm and term neonates with NHRF, who had an oxygenation index (OI) of ≥15 and <25 on two arterial blood gases and had not previously received INO, were randomly assigned to receive two doses of IPGE1 (300 and 150 ng/kg/min) or placebo. The primary outcome was the enrollment of 50 infants in six to nine months at 10 sites. The first pilot was halted after four months for failure to enroll a single infant. The most common cause for non-enrollment was prior initiation of INO. In a re-designed second pilot, co-administration of IPGE1 and INO was permitted. Infants with suboptimal response to INO received either aerosolized saline or IPGE1 at a low (150 ng/kg/min) or high dose (300 ng/kg/min) for a maximum duration of 72 hours. The primary outcome was the recruitment of an adequate number of patients (n = 50) in a nine-month-period, with fewer than 20% protocol violations. Results: No infants were enrolled in the first pilot. Seven patients were enrolled in the second pilot; three in the control, two in the low-dose IPGE1, and two in the high-dose IPGE1 groups. The study was halted for recruitment futility after approximately six months as enrollment targets were not met. No serious adverse events, one minor protocol deviation and one pharmacy protocol violation were reported. Conclusions: These two pilot RCTs failed to recruit adequate eligible newborns with NHRF. Complex management RCTs of novel therapies for persistent pulmonary hypertension of the newborn (PPHN) may require novel study designs and a longer period of time from study approval to commencement of enrollment. Trial registration: ClinicalTrials.gov: Pilot one: NCT number: 00598429. registered on 10 January 2008. Last updated: 3 February 2011.

KW - Aerosols

KW - Clinical trial

KW - Hypoxemic respiratory failure

KW - Nebulizers

KW - Neonatal

KW - Prostaglandins

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84928575200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928575200&partnerID=8YFLogxK

U2 - 10.1186/1745-6215-15-486

DO - 10.1186/1745-6215-15-486

M3 - Article

SP - 1

EP - 14

JO - Trials

JF - Trials

SN - 1745-6215

ER -